相关实验视频

Updated: May 8, 2026

An Orthotopic Mouse Model of Anaplastic Thyroid Carcinoma

An Orthotopic Mouse Model of Anaplastic Thyroid Carcinoma

Published on: April 17, 2013

在差异性甲状腺癌中对BRAF V600E和TERT突变分析的评估

Nigar Aktash¹, Ahmet Cem Dural², Husnu Aydin³

¹General Surgery, University of Health Sciences, Bakirkoy Dr. Sadi Konuk Training and Research Hospital, Istanbul, Türkiye. drngr.gsmv@gmail.com.

Updates in surgery

|October 22, 2025

概括

BRAF V600E突变与侵袭性分化甲状腺癌 (DTC) 和较大的瘤有关. 然而,BRAF和TERT突变对DTC患者的转移,复发或生存没有显著影响.

科学领域:

在瘤学瘤学.
遗传学是一个遗传学.
病理学病理学病理学

背景情况:

分化甲状腺癌 (DTC) 是最常见的甲状腺恶性瘤类型.
在DTC中经常观察到BRAF V600E瘤基因和TERT促进子突变.
了解这些突变与临床结果的关联对于患者管理至关重要.

研究的目的:

评估BRAF V600E和TERT促进子突变对差异化甲状腺癌的临床过程和侵略性传播的影响.
为了比较这些突变在攻击性DTC,标准DTC和良性甲状腺疾病中的患病率.

主要方法:

对137名患有分化甲状腺癌的患者进行了回顾性分析,这些患者接受了手术.
患者被分为攻击性DTC,标准DTC和良性对照组.
使用免疫组织化学工具包进行BRAF V600E和TERT促进体突变分析.

主要成果:

与其他群体相比,BRAF V600E突变在激进的DTC组 (1组) 中明显更普遍 (p=0.001).
BRAF和TERT突变与较大的瘤大小有关.
在BRAF阳性病例中,甲状腺外侵袭明显高 (p=0.029),但转移,复发和生存率没有显著差异.
TERT突变和BRAF+TERT同时发生在攻击性和标准DTC组之间没有显著差异.

结论:

BRAF V600E突变与侵袭性差异化甲状腺癌,瘤大小增加和甲状腺外侵袭有关.
在DTC中预测转移,复发和存活时,BRAF和TERT突变的临床实用性需要进一步研究.
需要进行全面的研究来评估常规BRAF和TERT突变测试在DTC管理中的临床益处.

关键词:

BRAF V600E 瘤基因检测仪有差异化的甲状腺癌.在 TERT 促销者突变中.

更多相关视频

Employing Digital Droplet PCR to Detect BRAF V600E Mutations in Formalin-fixed Paraffin-embedded Reference Standard Cell Lines

Employing Digital Droplet PCR to Detect BRAF V600E Mutations in Formalin-fixed Paraffin-embedded Reference Standard Cell Lines

Published on: October 8, 2015

Spontaneous Murine Model of Anaplastic Thyroid Cancer

Spontaneous Murine Model of Anaplastic Thyroid Cancer

Published on: February 3, 2023

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...